A groundbreaking study reveals that the drug Sunleca (lenacapavir), administered via injection twice a year, offers 100% protection against HIV in females. This discovery could revolutionize HIV prevention and drastically reduce new infections worldwide.
Twice-a-Year Shot Provides 100% HIV Protection, Study Finds
A new clinical study has demonstrated that the injectable drug Sunleca (lenacapavir) offers 100% protection against HIV in females when administered twice a year. This remarkable finding, presented at the Aids 2024 conference in Munich, has generated widespread excitement and optimism among health experts and researchers.
The Study and Its Impact
Led by Prof. Linda-Gail Bekker, CEO of the Desmond Tutu Health Foundation, the Purpose 1 trial involved over 5,000 young women aged 16 to 25 from South Africa and Uganda. The participants received injections of lenacapavir every six months. Notably, none of the women who received the injections contracted HIV, contrasting sharply with a control group taking daily oral PrEP pills, where some new infections occurred. The trial’s success prompted a standing ovation for Bekker, who emotionally shared her personal connection to the HIV epidemic.
A Revolutionary Approach to HIV Prevention
The introduction of lenacapavir as a preventive measure could transform the landscape of HIV prevention, especially in regions with high infection rates. One of the major challenges with current PrEP methods is adherence; daily pills can be burdensome and difficult for many to maintain consistently. In contrast, the biannual injection of lenacapavir simplifies the regimen, offering a discreet and long-lasting option for protection.
Challenges and Future Prospects
Despite the promising results, several challenges remain. The cost of lenacapavir is currently high, with estimates around $40,000 per year, though it could potentially be produced for as little as $40. Gilead, the drug’s manufacturer, has expressed intentions to collaborate with other companies to ensure affordable, generic versions of the drug are made available, particularly in low- and middle-income countries.
The trial’s success has led to calls for swift regulatory approval and wide-scale distribution. However, the study’s findings have so far been limited to females. Ongoing research, including the Purpose 2 trial, is examining the drug’s efficacy in males, transgender women, and non-binary individuals, with results expected later this year.
A Global Health Milestone
The discovery of lenacapavir’s effectiveness is not just a scientific breakthrough; it’s a potential game-changer in the fight against HIV. With nearly 39 million people living with HIV worldwide and new infections disproportionately affecting young women in sub-Saharan Africa, this new preventive measure could save countless lives.
Health experts are hopeful that this biannual injection could become a key tool in global HIV prevention efforts, reducing new infections and offering a new level of autonomy and protection to those at risk. As the world watches and waits for broader accessibility, the promise of lenacapavir shines as a beacon of hope in the ongoing battle against HIV/AIDS.
References:
- Twice-a-year shot provides 100 percent HIV protection, study finds – Washington Post
- A ‘miracle’ HIV shot, surprising shingles vaccine benefit and health-threatening wildfires: What to know about this week’s health news – Yahoo News
- Doctor behind trial of HIV prevention drug recounts breakthrough moment – The Guardian
- Twice-Yearly Shot 100% Successful at Preventing HIV in Women – Healthline
